First line IO102-IO103 vaccine plus pembrolizumab in advanced melanoma скачать в хорошем качестве

First line IO102-IO103 vaccine plus pembrolizumab in advanced melanoma

Ines Pires da Silva, MD, PhD, Melanoma Institute Australia, Sydney, Australia, explores the Phase III IOB-013/KN-D18 trial (NCT05155254) evaluating IO102-IO103, a cancer vaccine targeting IDO1+ and PD-L1+ cells with pembrolizumab as first-line therapy for advanced melanoma. The combination showed a clinically meaningful improvement in progression-free survival compared with pembrolizumab alone, including in PD-L1–negative patients, and was well tolerated without added systemic toxicity. Vaccine-specific T cells were significantly expanded, highlighting the potential of IO102-IO103 to enhance anti-tumor immune responses in advanced melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.